<DOC>
	<DOCNO>NCT01291004</DOCNO>
	<brief_summary>This study conduct evaluate impact 28-day oral contraceptive compare two 28-day oral contraceptive regimen contain different synthetic progestin ovarian follicular activity hormone level healthy woman .</brief_summary>
	<brief_title>A Study Evaluate Ovarian Follicular Activity Hormone Levels DR-102 Compared Two 28-Day Oral Contraceptives</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Premenopausal , nonpregnant , nonlactating woman age 1835 year old Body Mass Index ( BMI ) ≥18 kg/m² &lt; 30 kg/m² Regular spontaneous menstrual cycle Others dictate Food Drug Administration ( FDA ) approve protocol Any condition contraindicates use combination oral contraceptive Known thrombophlebitis thromboembolic disorder ; know suspect clot disorder ; thrombogenic valvulopathies rhythm disorder Migraine headaches focal , neurological symptom Others dictate FDAapproved protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>